1-3 of 3
Donne Bennett Caces
Close
Sort by
Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Carol Moreno, Talha Munir, Carolyn Owen, George Follows, Jose-Angel Hernandez Rivas, Ohad Benjamini, Ann Janssens, Mark-David Levin, Tadeusz Robak, Martin Simkovic, Sergey Voloshin, Vladimir I. Vorobyev, Munci Yagci, Loic Ysebaert, Qianya Qi, Emma Smith, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2023) 142 (Supplement 1): 634.
https://doi.org/10.1182/blood-2023-177713
Published: 2023
Journal Articles

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Carsten U Niemann, Talha Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Österborg, Tadeusz Robak, Martin Šimkovič, Sergey Voloshin, Vladimir I. Vorobyev, Munci Yagci, Loic Ysebaert, Keqin Qi, Qianaya Qi, Lori Parisi, Srimathi Srinivasan, Natasha Schuier, Kurt Baeten, Angela Howes, Donne Bennett Caces, Arnon P. Kater
Journal: Blood
Blood (2022) 140 (Supplement 1): 228–230.
https://doi.org/10.1182/blood-2022-156070
Published: 2022
Journal Articles

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Tahla Munir, Carol Moreno, Carolyn Owen, George A Follows, Ohad Benjamini, Ann Janssens, Mark-David Levin, Anders Österborg, Tadeusz Robak, Martin Simkovic, Don Stevens, Sergey Voloshin, Vladimir I. Vorobyev, Munchi Yagci, Loic Ysebaert, Qianaya Qi, Andrew Steele, Natasha Schuier, Kurt Baeten, Donne Bennett Caces, Carsten Utoft Niemann, Arnon P. Kater
Journal: Blood
Blood (2021) 138 (Supplement 1): 70.
https://doi.org/10.1182/blood-2021-148666
Published: 2021